For instance, immunohistochemical determination of PD-L1 expression is technically challenging and, in general, pathological scoring is impacted by tumor heterogeneity and displays only moderate correlation with response to PD-1/PD-L1 blockade clinically14. Here, PDCD1 is linked to neoplasm.